Cargando…
Current available therapies and future directions in the treatment of malignant gliomas
The prognosis of patients diagnosed with malignant glioma (MG) remains poor. However, recent advances in neuro-oncology allowing a better understanding of this particular disease have allowed the development of new therapeutics. Many molecular genetic and signal transduction pathway targets have bee...
Autores principales: | Desjardins, Annick, Reardon, David A, Vredenburgh, James J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726053/ https://www.ncbi.nlm.nih.gov/pubmed/19707392 |
Ejemplares similares
-
Current and Future Gene Therapy for Malignant Gliomas
por: Kanzawa, Takao, et al.
Publicado: (2003) -
Interstitial chemotherapy with biodegradable BCNU (Gliadel(®)) wafers in the treatment of malignant gliomas
por: Bota, Daniela A, et al.
Publicado: (2007) -
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
por: Affronti, Mary Lou, et al.
Publicado: (2018) -
A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab
por: Affronti, Mary Lou, et al.
Publicado: (2016) -
Diffuse intrinsic pontine glioma: current insights and future directions
por: Srikanthan, Dilakshan, et al.
Publicado: (2021)